Jigsaw Medical

jigsawmedical.com

Founded in 2012 by Chris Percival, Jigsaw Medical has quickly become one of the UK leaders in medical services, offering a range of services for the commercial, media, events sectors and the NHS. Jigsaw Medical is divided into three clear entities; our Clinical Services Division, Training Division, and our Specialist Projects Division. We are committed to delivering clinically focused and harmonised solutions to both NHS and private clients. Our Clinical Services Division specialises in providing ambulance services, event medical cover, and TV / Film unit medics whilst our Training Division provides first aid training courses and clinical education. Finally, our Special Projects Division provides specific medical training and medical staff for close protection, hostile, and remote environments – making up our four clear divisions.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

MEDIKARMA SELECTS 1UPHEALTH AS ITS INTEROPERABILITY PARTNER TO HELP PATIENTS ACQUIRE THEIR MEDICAL RECORDS FROM HOSPITAL EMRS

1upHealth | June 07, 2022

news image

MediKarma, Inc, a global leader in an AI-based patient engagement, education and navigation platform, has selected 1upHealth, the market leader offering healthcare's most complete FHIR® data platform, as its interoperability partner to help patients request and acquire their medical records through FHIR-based APIs. Fast Healthcare Interoperability Resources (FHIR®) is the future of healthcare that brings together claims and clinical information in one common standard to drive innovat...

Read More

Cell and Gene Therapy

SYSMEX AND THINKCYTE HAVE ENTERED INTO AN AGREEMENT FOR JOINT DEVELOPMENT AND CAPITAL ALLIANCE

Sysmex Corporation | May 17, 2021

news image

Sysmex Corporation and ThinkCyte, Inc. announced today the signing of joint development and investment agreements for the commercialization of an AI-based cell analysis technology in May 2021. The development of novel testing and diagnostic technologies of high clinical utility is being pursued to improve the precision of diagnoses and maximize treatment as healthcare becomes more accurate and personalized at an increased pace - in combination with the advancement of technology. M...

Read More

Medical

SLINGSHOT BIOSCIENCES, INC. PARTNERS WITH CAMBRIDGE BIOSCIENCE TO DISTRIBUTE SYNTHETIC CELLS THROUGHOUT UNITED KINGDOM AND IRELAND

Slingshot | June 16, 2022

news image

SLINGSHOT BIOSCIENCES, INC. the makers of synthetic cells that bring consistent precision and accurate control to replace inconsistent blood and tissue controls for use in flow cytometry and other biotech markets, today announced they have extended their distribution channel through a new agreement with Cambridge Bioscience, a UK-based specialist distributor of life science research tools. The agreement entitles Cambridge Bioscience to the right to distribute and resell Slingshot ...

Read More

Medical

TARGETING CHRONIC INFECTIONS IN CYSTIC FIBROSIS, CYSTIC FIBROSIS FOUNDATION INVESTED IN FELIX BIOTECHNOLOGY

Felix Biotechnology | March 07, 2022

news image

Felix Biotechnology, a biopharmaceutical business focusing on developing first-in-class, long-lasting antibacterial medicines to treat chronic drug-resistant infections, announced that it has received a Therapeutics Development Award from the Cystic Fibrosis Foundation. The funding will aid Felix's efforts to develop a novel medication to treat chronic Pseudomonas aeruginosa lung infections. Chronic P. aeruginosa infections affect half of the persons with cystic fibrosis, many...

Read More
news image

Medical

MEDIKARMA SELECTS 1UPHEALTH AS ITS INTEROPERABILITY PARTNER TO HELP PATIENTS ACQUIRE THEIR MEDICAL RECORDS FROM HOSPITAL EMRS

1upHealth | June 07, 2022

MediKarma, Inc, a global leader in an AI-based patient engagement, education and navigation platform, has selected 1upHealth, the market leader offering healthcare's most complete FHIR® data platform, as its interoperability partner to help patients request and acquire their medical records through FHIR-based APIs. Fast Healthcare Interoperability Resources (FHIR®) is the future of healthcare that brings together claims and clinical information in one common standard to drive innovat...

Read More
news image

Cell and Gene Therapy

SYSMEX AND THINKCYTE HAVE ENTERED INTO AN AGREEMENT FOR JOINT DEVELOPMENT AND CAPITAL ALLIANCE

Sysmex Corporation | May 17, 2021

Sysmex Corporation and ThinkCyte, Inc. announced today the signing of joint development and investment agreements for the commercialization of an AI-based cell analysis technology in May 2021. The development of novel testing and diagnostic technologies of high clinical utility is being pursued to improve the precision of diagnoses and maximize treatment as healthcare becomes more accurate and personalized at an increased pace - in combination with the advancement of technology. M...

Read More
news image

Medical

SLINGSHOT BIOSCIENCES, INC. PARTNERS WITH CAMBRIDGE BIOSCIENCE TO DISTRIBUTE SYNTHETIC CELLS THROUGHOUT UNITED KINGDOM AND IRELAND

Slingshot | June 16, 2022

SLINGSHOT BIOSCIENCES, INC. the makers of synthetic cells that bring consistent precision and accurate control to replace inconsistent blood and tissue controls for use in flow cytometry and other biotech markets, today announced they have extended their distribution channel through a new agreement with Cambridge Bioscience, a UK-based specialist distributor of life science research tools. The agreement entitles Cambridge Bioscience to the right to distribute and resell Slingshot ...

Read More
news image

Medical

TARGETING CHRONIC INFECTIONS IN CYSTIC FIBROSIS, CYSTIC FIBROSIS FOUNDATION INVESTED IN FELIX BIOTECHNOLOGY

Felix Biotechnology | March 07, 2022

Felix Biotechnology, a biopharmaceutical business focusing on developing first-in-class, long-lasting antibacterial medicines to treat chronic drug-resistant infections, announced that it has received a Therapeutics Development Award from the Cystic Fibrosis Foundation. The funding will aid Felix's efforts to develop a novel medication to treat chronic Pseudomonas aeruginosa lung infections. Chronic P. aeruginosa infections affect half of the persons with cystic fibrosis, many...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us